Scholarlink

<p>Radiotherapy is a crucial therapeutic approach for the management of non-small cell lung cancer (NSCLC). Nevertheless, the radioresistance of NSCLC, particularly in cases involving the gain-of-function mutant p53, substantially limits its efficacy. According to recent research, mutant p53 R273H can recruit poly (ADP-ribose) polymerase (PARP)-1 on replicating DNA to promote tumor survival. Whether mutant p53 R273H-mediated radioresistance is related to the interaction between mutant p53 R273H and PARP1, and if PARP1 inhibitors (PARPi) can increase the radiosensitivity of mutant p53 R273H-expressing tumors have not been explored. Through in vitro and in vivo experiments, we determined that mutant p53 R273H promotes radioresistance in NSCLC by partially inhibiting ferroptosis through the SLC7A11/GSH/GPX4 axis, independently of PARP1, whereas FZ counteracts this effect by partially blocking the same axis to promote ferroptosis, presenting a potential novel strategy for treating NSCLC patients with gain-of-function mutant p53 R273H.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Fuzuloparib enhances radiosensitivity of gain-of-function mutant p53 R273H NSCLC by promoting SLC7A11/GSH/GPX4 axis mediated ferroptosis

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年6月1日

查看全文
  • Mengjia Wu,
  • Chaoyuan Pu,
  • Wanxuan Weng,
  • Fengmin Yin,
  • Lei Zhang,
  • Chenggang Xu,
  • Mingjian Li,
  • Chuanhui Cao,
  • Wei Hu

摘要

Radiotherapy is a crucial therapeutic approach for the management of non-small cell lung cancer (NSCLC). Nevertheless, the radioresistance of NSCLC, particularly in cases involving the gain-of-function mutant p53, substantially limits its efficacy. According to recent research, mutant p53 R273H can recruit poly (ADP-ribose) polymerase (PARP)-1 on replicating DNA to promote tumor survival. Whether mutant p53 R273H-mediated radioresistance is related to the interaction between mutant p53 R273H and PARP1, and if PARP1 inhibitors (PARPi) can increase the radiosensitivity of mutant p53 R273H-expressing tumors have not been explored. Through in vitro and in vivo experiments, we determined that mutant p53 R273H promotes radioresistance in NSCLC by partially inhibiting ferroptosis through the SLC7A11/GSH/GPX4 axis, independently of PARP1, whereas FZ counteracts this effect by partially blocking the same axis to promote ferroptosis, presenting a potential novel strategy for treating NSCLC patients with gain-of-function mutant p53 R273H.